Ljubljana

• CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Not authorised
  2023-506019-16-01 7 TRIPLE NEGATIVE BREAST CANCER
• EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with e … Not authorised
  2024-513442-10-00 5 ER positive HER2 negative breast cancer stages I-II
• CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Pending
  2023-506019-16-03 7 TRIPLE NEGATIVE BREAST CANCER
• ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending
  2024-513824-41-00 6 Childhood non-mature-B Acute Lymphoblastic Leukemia
• Effect of perioperative intravenous infusion of lidocaine on the postoperative course and the immune response in patients undergoing surgery … Pending
  2025-521808-22-01 4 Colon cancer
• Treatment of low-flow vascular malformations with bleomycin electrosclerotherapy (BEST) Pending
  2025-524123-45-00 4 VASCULAR MALFORMATION
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano … Recruiting
  2022-503140-41-00 5 2025-12-19 Melanoma
• SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting
  2025-520794-39-00 5 2025-12-10 Arterial Hypertension
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formu … Recruiting
  2023-510017-26-00 1 2024-10-02 Completely Resected Stage IIB, IIC, and III Melanoma
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 Ulcerative Colitis
• Effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans … Recruiting
  2023-508694-80-01 6 2024-06-18 Patients undergoing antibiotic therapy (in the context of erythema mig
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
• Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neona … Recruiting
  2023-504307-88-00 5 2024-02-20 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly … Recruiting
  2022-500275-31-00 5 2023-06-20 Haemophilia A
• A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Ope … Recruiting
  2023-509672-42-00 5 2023-02-02 GRIN-related neurodevelopmental disorder
• SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting
  2025-521560-36-00 4 2026-04-22 Type 1 Diabetes
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting
  2024-517614-14-00 4 2025-11-28 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Showing 1–24 of 88 trials